02268 WUXI XDC
- 17.500
- +0.660+3.92%
WUXI XDC News
[Brokerage Focus] Bocom Intl expects current high cost performance in medical sector, but industry sentiment has not fully recovered.
Jingu Finance Xintong | Bank of Communications International released the outlook for the pharmaceutical industry in the second half of 2024. They think that the pharmaceutical sector currently has high cost-effectiveness, but institutional positions have fallen to a low level and industry sentiment has not fully recovered. The bank recommends laying out three main themes in 2H24: 1) The Davis double-click opportunity of valuation bottoming out and performance rebounding; 2) Innovation is the theme of the industry's long-term development, taking into account the potential for product export; 3) Defensive opportunities with stable performance and high shareholder returns. The bank's preference ranking for segmented sectors is as follows: prescription drugs = innovative drugs > high dividend traditional Chinese medicine/circulation > private hospitals > CXO. Specifically, prescription drugs - performance growth rebound + valuation.
Changes in Hong Kong stocks | Yao Ming Union (02268) is now up more than 6%. The company is benefiting from the booming development of the ADC industry and the construction of a production base in Singapore begins
The Zhitong Finance App learned that Yao Ming United (02268) is now up more than 6%. As of press release, it has risen 5.63% to HK$15.76, with a turnover of HK$37.474 million. Huachuang Securities pointed out that oncology immunotherapy (IO) has become the cornerstone of the field of oncology. It has been approved for the treatment of more than 20 types of cancer, and the global annual sales volume exceeds 40 billion US dollars. IO+ADC has become the main line of tumor immunity in the next 5-10 years; of the current IO therapies, nearly half of the current IO therapies may be upgraded from IO+ chemotherapy to IO+ADC, and the relevant indication market is expected to expand by 100-200%; China ADC
WuXi XDC Cayman Inc.'s (HKG:2268) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
WuXi XDC Cayman Inc. (HKG:2268) shareholders won't be pleased to see that the share price has had a very rough month, dropping 26% and undoing the prior period's positive performance. Longer-term s
Read This Before Judging WuXi XDC Cayman Inc.'s (HKG:2268) ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). To keep the less
WuXi XDC Cayman's Profit Up 82% in 2023
WuXi XDC Cayman (HKG:2268) recorded an 82% rise in attributable profit for the year 2023 to 283.5 million yuan from 155.7 million yuan in 2022, according to the company's annual report posted on the H
[Broker Focus] Minsheng Securities indicates that Pharmaceutical Federation (02268) has drastically raised the upper limit of raw material purchase agreements and maintained a “recommended” rating
Jinwu Financial News | According to the Minsheng Securities Research Report, the Pharmaceutical Federation (02268) issued an announcement to raise the upper limit of the raw material procurement service agreement from 32.6 million yuan to 80 million yuan (+145%) in 2024, and raise the upper limit from 21.3 million yuan to 75 million yuan (+252%) in 2025. Demand for raw materials from Yao Ming Biotech has further increased, and all terms and conditions of the procurement service agreement have remained unchanged. The bank indicates that in order to meet customer needs, companies must promptly purchase relevant raw materials and make inventory reserves to ensure the normal progress of the existing XDCCRDMO project
藥明合聯：2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Yao Ming Union (02268) surged more than 5% in the afternoon, and the company achieved a further breakthrough in the ADC CRDMO business after the listing
The Zhitong Finance App learned that Yao Ming United (02268) surged by more than 5% in the afternoon. As of press release, it had risen 5.01% to HK$17.6 million, with a turnover of HK$2016.67 million. Guoxin Securities pointed out that as the ADC CRDMO leader with a global layout, Pharmaceutical Federation has established a fully integrated one-stop CRDMO platform, covering the entire ADC CRDMO service process and leading the world in comprehensive capabilities. As the company's global production capacity continues to expand and pre-IND projects continue to advance to the post-IND stage, we believe that the company's business will maintain rapid growth over the next 3 years. Tianfeng Securities, on the other hand, said that
Cansino Biotech (06185), the leading healthcare market, surged 15.12%, and Beijing, Guangzhou, and Zhuhai issued pharmaceutical innovation support policies
Jinwu Financial News | The healthcare sector led the market. Hang Seng Healthcare Index rose 1.93%. Among the constituent stocks, Cansino Biotech (06185) rose 15.12%, Junshi Biotech (01877) rose 11.9%, Genting Xinyao (01952) rose 7.8%, Yiming Angke (01541) rose 7.79%, Pharmaceuticals (02268) rose 5.98%, and Tiger Pharmaceuticals (03347) rose 5.8%. According to the news, the Beijing Municipal Medical Security Administration issued “On “Certain Measures to Support the High-Quality Development of Innovative Pharmaceuticals by 9 Departments Including the Beijing Municipal Medical Security Administration” (202
Changes in Hong Kong stocks | Yao Ming Union (02268) rose more than 6%. Institutions believe that performance is high, growth expectations have been fulfilled, and that current stock prices are still significantly undervalued
Pharmaceutical Federation (02268) rose more than 6% and rose 6.57% at press time to report HK$18.16, with a turnover of HK$18.65 million.
Changes in Hong Kong stocks | Pharmaceutical Federation (02268) rose more than 5%, annual performance growth was strong, and the number of projects at all stages remained high
Pharmaceutical Federation (02268) rose more than 5%. As of press release, it was up 5.17% to HK$17.48, with a turnover of HK$585.34,900.
[Broker Focus] Minsheng Securities maintains the “Recommended” rating of Pharmaceutical Federation (02268), indicating that the performance exceeded expectations
Jinwu Financial News | According to Minsheng Securities Research Report, Yao Ming Union (02268) released its 2023 annual report. The company achieved annual sales revenue of 2,124 billion yuan, a strong year-on-year increase of 114.4%, gross profit of 560 million yuan, a year-on-year increase of 114.3%, net profit of 284 million yuan, an increase of 82.1% year-on-year, and adjusted net profit of 412 million yuan, an increase of 112.1% year on year. The performance exceeded expectations. According to the bank, newly signed projects and funnel pipelines continue to grow significantly, and late-clinical and PPQ projects reserve commercial potential. In addition, the Wuxi base achieved a one-stop production layout and Singaporean business
BOC International: Maintaining the Target Price of HK$42 for the “Buy” Rating of Pharmaceutical Plus (02268)
The Zhitong Finance App learned that BOC International released a research report saying that considering the company's continued growth in large orders in the later stages and the high degree of certainty that performance expectations will be fulfilled, the current stock price is still significantly undervalued, maintaining the “buy” rating of Pharmaceutical Federation (02268). The 2024-25E revenue forecast remains unchanged. Based on the gradually improved profit margin forecast, the adjusted net profit forecast was raised 2%-3% to 780 million/1.17 billion yuan. The latest revenue/adjusted net profit forecasts correspond to 47%/60% 2023-26 ECAGR, respectively, with a target price of HK$42. BOC International's main views are as follows: FY23 Super
WuXi XDC Cayman's 2023 Revenue More Than Doubled
By Amanda Lee WuXi XDC Cayman's 2023 revenue more than doubled, thanks to the increased number of customers and projects, as well as advancement of projects. The Chinese biotech company's 2023 reven
WuXi XDC Delivers Outstanding Performance in 2023 With Over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones
WuXi XDC Cayman Inc. ("WuXi XDC" or "the Group", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization ...
Pharmaceutical Federation (02268.HK) annual owners should account for an adjusted net profit of 412 million yuan, an increase of 112.1% year-on-year
Gelonghui, March 25 | Pharmaceutical Federation (02268.HK) announced that for the year ended December 31, 2023, the company has achieved impressive results. In particular, adjusted net profit attributable to company owners grew strongly, reaching RMB 412.3 million, which is equivalent to a year-on-year increase of 112.1%. In addition, the Group's revenue and gross profit also showed strong growth in 2023, with year-on-year increases of 114.4% and 114.3%, respectively, to RMB2,123.8 million and RMB559.6 million. The Board does not recommend any payments for the year ended 31 December 2023
WUXI XDC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Changes in Hong Kong stocks | Pharmaceutical Alliance (02268) continues to rise by more than 9%, global bioconjugated drug CRDMO service leader, abundant orders guarantee high performance growth
Pharmaceutical Federation (02268) continued to rise by more than 9%. As of press time, it rose 9.48% to HK$17.1, with a turnover of HK$1.89 million.
Analysis
Price Target
No Data
